Cargando…
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
In this Phase 2 study, we evaluated the efficacy of combination of 5-azacitidine (AZA), valproic acid (VPA), and all-trans retinoic acid (ATRA) in patients with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Treatment consisted of six cycles of AZA and VPA for 7 days, foll...
Autores principales: | Raffoux, Emmanuel, Cras, Audrey, Recher, Christian, Boëlle, Pierre-Yves, de Labarthe, Adrienne, Turlure, Pascal, Marolleau, Jean-Pierre, Reman, Oumedaly, Gardin, Claude, Victor, Maud, Maury, Sébastien, Rousselot, Philippe, Malfuson, Jean-Valère, Maarek, Odile, Daniel, Marie-Thérèse, Fenaux, Pierre, Degos, Laurent, Chomienne, Christine, Chevret, Sylvie, Dombret, Hervé |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053545/ https://www.ncbi.nlm.nih.gov/pubmed/21293051 |
Ejemplares similares
-
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia
por: Vidal, Valérie, et al.
Publicado: (2017) -
Transfusion strategy in hematological intensive care unit: study protocol for a randomized controlled trial
por: Chantepie, Sylvain P., et al.
Publicado: (2015) -
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies
por: Ades, Lionel, et al.
Publicado: (2017) -
Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group
por: Adès, Lionel, et al.
Publicado: (2018) -
Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia
por: Pautas, Cécile, et al.
Publicado: (2021)